Good day, and thank you for standing by. Welcome to the Privia Health Fourth Quarter Conference Call. At this time all participant lines are in listen-only mode. [Operator Instructions]. I'd now like to hand the conference over to your host today, Robert Borchert, Senior Vice President, Investor and Corporate Communications. Please go ahead.

Thank you, Liz, and good morning, everyone. Joining me today are Shawn Morris, our Chief Executive Officer; Parth Mehrotra, President and Chief Operating Officer; and David Mountcastle, our Chief Financial Officer. This call is being webcast and can be accessed from the Investor Relations section of priviahealth.com. Today's press release highlighting our financial and operating performance, as well as the slide presentation accompanying our formal remarks, are posted on our IR website pages. Following our prepared comments, we will open the line for questions. We ask you to please limit yourself to one question and one follow-up so we can get through the full queue in a timely fashion. The financial results reported today and in the press release are preliminary and are not final to our Form 10-K for the year ended December 31, 2021, is filed with the Securities and Exchange Commission. Some of the statements we will make today are forward-looking in nature based on our current expectations and our view of our business as of March 23, 2022. Such statements, including those related to our future financial and operating performance and future business plans and objectives, are subject to risks and uncertainties that may cause actual results to differ materially. As a result, these statements should be considered in conjunction with the cautionary statements in today's press release and the risk factors described in our company's most recent SEC filings. Finally, we may refer to certain non-GAAP financial measures on the call. And reconciliations of these measures to comparable GAAP measures are included in our press release and the accompanying slide presentation posted on our website. Now, I'll turn the call over to Shawn.

Thank you, Robert, and good morning, everyone. Today, I'm excited to report that Privia Health delivered another strong quarter financial and operating performance in Q4. And our full year financial results were above the high end of our previous guidance. This performance positions our company for accelerated growth in 2022 as we continue to build a national position organization, engage with, and organize physicians into scaled provider networks across our country. Today, I'll provide an overview of key highlights that are driving our continued business momentum. David will cover our recent financial performance. And then Parth will discuss our outlook for 2022 and conclude with a more detailed business update on our growth drivers and value-based care initiatives before we take your questions. We also announced that Jeff Sherman resigned from his position of Chief Financial Officer to pursue other opportunities. Jeff joined in January this year, and his departure was not a result of any disagreements or issues with regard to Privia Health's operations or accounting policies and practices. Following Jeff's decisions, we appointed David Mountcastle, Executive Vice President and Chief Financial Officer. David joined Privia in 2014 as our CFO, and he has an intimate understanding of our company's business operations and financial and accounting practices. Importantly, we are on track to file our 10-K later this week as originally planned. We remain very excited about our business momentum, and our financial performance will speak for itself. Now on to our business highlights. Privia Health executed at a very high level in our first year as a public company. We have materially advanced our business entering three new markets in the last five months, adding close to 500 physicians and providers through our anchored partnerships in California, Montana and West Texas. Long term, our strategy is to align…

Thanks, Shawn. Privia is addressing a significant market opportunity and is well positioned to capitalize on the growing shift to value-based care with health plans, providers and physician groups looking for help in navigating this transition. Our performance through 2021 underscores this with guidance raised in each of the last three quarters and culminating with above guidance results for the full year. Our operating momentum continued to drive strong results in the fourth quarter. Practice collections were $513 million, a 45.8% increase from Q4, a year ago. Care margin increased 33.8%, and adjusted EBITDA was $7.5 million, an increase of 18.2% over the prior year. EBITDA was down sequentially from Q3 to Q4 due to our outperforming Q3 related to our MSSP shared savings results as well as the expected new market entry cost in Q4 that we discussed last quarter. New market entries are part of our ongoing strategy, so we do not add back these costs to arrive at adjusted EBITDA. We also increased our quarterly bonus accruals by an incremental $2 million in the fourth quarter based on our strong full year performance. So if you spread this incremental expense over the quarters, Q4 adjusted EBITDA would have been $1.5 million higher than the reported number. For full year 2021, our 30.1% growth in Implemented Providers and 15.2% increase in value-based attributed lives, combined with ambulatory patient volumes, led to all of our financial results being at the high end of our previous guidance. Practice collections increased 25%, which was 5.5% above the top end of our guidance at Q3 and 11% higher than the top end of our initial guidance back in May. Care margin was up 27.1% and adjusted EBITDA grew 40.9%. Our adjusted EBITDA margin reached 17.4% of care margin, a 170 basis point increase year-over-year which highlights the operating leverage of our model. One of Privia Health's key differentiators is our solid balance sheet and positive cash flow. We ended 2021 with a net cash position of more than $287 million and significant cash flow generation heading into 2022. Cash flow from operations was $55 million, an increase of 41.6% from 2020. With capital expenditures of less than $1 million, free cash flow was $54.6 million. Our strong performance positions Privia very well as we move into 2022. We continue to gain traction with providers looking to partner with scaled, financially sound organization to improve outcomes for their entire patient population. With our liquidity strength, low leverage and a strong cash position, we are highly confident in our ability to fund all of our growth initiatives and opportunities, including new market development and strategic investments. Now I'd like to ask Parth to discuss our 2022 outlook and update you on our growth drivers and value-based care initiatives.

Thanks, David. We are excited about our recent performance and operating momentum heading into 2022. We intend to continue this success by growing within existing practices, increasing attribution and risk-based contracts, adding new providers, opening new markets and identifying opportunities to expand our platform. For 2022, implemented providers is expected to reach 3,675 with attributed lives increasing to 875,000 at the midpoint, which is double-digit year-over-year growth. We expect practice collections to grow 30.7% to more than $2.1 billion and adjusted EBITDA to increase 30.4%, both at the midpoint of our guidance. We plan to invest across our business enterprise in sales and leadership, clinical and operational performance talent and our technology infrastructure to support this accelerating top line growth. We expect practice collections and GAAP revenue to ramp through the year and adjusted EBITDA to follow as newly signed providers are implemented and come online at the full top line run rate. Beginning in Q1, we anticipate reporting our capitated revenue as a new line item in the sources of revenue section of our 10-Q. We also expect to rename our physician and practice expense line to provider expense, which will capture the complete medical cost related to the at-risk capitated contracts. Here are several assumptions underlying our 2022 guidance. Our growth outlook includes the impact of our new capitated agreements and only previously announced new market entries. Adjusted EBITDA guidance includes approximately $4 million to $6 million in accelerated investment spend. This is to support our recently announced new market expansions and value-based care initiatives, all of which were ahead of our expectations from a timing perspective. We are making prudent financial assumptions for this first year of our new capitated agreements and are resuming minimal incremental care margin and EBITDA contribution at this point in 2022. We…

Our first question comes from Josh Raskin with Nephron Research.

Hi, thanks. Good morning. My first question is, how many of those 3,700 implemented providers this year, sort of midpoint of guidance, will be in global cap arrangements? And what's a reasonable cadence of growth over the next full years? I fully understand it's lumpy. So kind of just looking for averages?

Yes. Thanks, Josh. I'll start and Shawn can add. We don't split out how many providers. Typically, 70% of our provider base is, as you know, what we call gatekeeper providers, primary care, internal medicine, family medicine, pediatricians and OB/GYNs, and 30% plus are specialists in some nature. A subset of our PCPs, both in Mid-Atlantic and in Florida, will be in those global cap arrangements. So it's obviously going to be a pretty small number. It's about 23,000 lives as we articulated in our press release earlier this year.

Okay. And is the idea -- I know the idea is sort of convert these lives, but is it more a focus on getting the provider ready to do that? As I assume that's kind of the -- sort of operations or of operations, right, that you have to get the provider to take the risk and then kind of the lives follow. Is that the right way to think about it?

Yes, Josh, this is Shawn. Think about -- I think it's obviously the provider, you're familiar with that slide. We've presented multiple times kind of the first couple of buckets of getting the technology in place, stabilizing the practice, teaching them get the cash flow that in moving them up the risk spectrum. So obviously, there's a provider element to that. But there's also a payer element to that, making sure that we're confident they're going to get us the right data making sure we have the arrangement, the right contractual arrangements that they're going to kind of stand up to, and we've been pretty upfront about the type of range as we like or where the payers still have some risk in that and that we're operating all within aligned incentives down -- from payer all the way down to provider.

Got you. And then just a quick follow-up. I think I heard you say that the healthcare utilization, your fee-for-service trends were running above the pre-pandemic baselines. I want to make sure I understood that. Is that -- do you think overall health care utilization is now back to or above baseline, or was that just your providers are taking market share, and so they're actually doing more business than they were pre-pandemic?

Yes. I think it's important to identify the two buckets of broad utilization. One is where we are concerned is ambulatory utilization in a community docs that we have at Privia. And we think that utilization is pretty much back as we experienced seasonally adjusted at above the pre-COVID baseline, it was better than expected despite the recent variant in Q4 and Q1. The inpatient utilization trends or facility base still varies by geography and probably gets more impacted. That obviously does not impact our providers as much. And so I think that's the key difference.

Yes, Josh. The only thing I would add, as you know, you have been in covered managed care a long time, access is absolutely critical. We worked with our providers in the last couple of years at COVID and up until now. And as you know, we introduced very early on, the ability for virtual care and all those things. So I think they're utilizing a lot of those aspects, getting their patients in. And it's what I think we did, like we said, take some market share, and we're seeing that ambulatory utilization up, which is, we think, is a very good thing, especially in our value-based arrangements.

Perfect. Thanks.

Our next question comes from Whit Mayo with SVB Securities.

Thanks. Good morning. The first question I have is just around the ACOs. And as you look at the financial performance, standing up and starting your historical ACOs. Is there any reason that we shouldn't look at that as a guidepost for what the performance should be this year, do you think you can do better? And really the corollary to this question is also in the transition towards the Enhanced Track and why your experience in the new three ACOs moving into Enhanced Track may or may not be any different than your experience in the Mid-Atlantic?

Yes. Thanks for the question, Whit. It's Parth. Yes, I think it's an important point to note, we are obviously much more mature as an organization today relative to what we were five years ago when we first started in Mid-Atlantic. So that would manifest itself in two particular areas as it pertains to this question. One is our ability to take on more risk sooner and the capabilities that we've developed are obviously much better. So it allows us to do that sooner than what we were at five or six years ago. And that would mean moving these -- the new ratios in to Enhanced Track sooner. Obviously, it depends -- the answer also depends on the geography. No two geographies are the same. We look at the patient pools. We look at our provider density. We look at the payer relationship in any particular market. All else being equal, you should expect we would accelerate that move given the maturity of the organization, but it will depend by the geography.

Okay. That's helpful. Second question, just around the investments that you're making, not terribly surprising, but I think it might be helpful just to maybe break out a little bit more discreetly some of the buckets. And I'm just wondering if I take $5 million at the midpoint. How much of that should we look at as perhaps being really onetime and thinking -- I mean I think that as you move into new markets, some of this is probably going to continue to repeat itself. So I'm just trying to make sure I properly understand exactly what -- where the $5 million is going?

Yes, definitely. So number one, it's fairly broad-based. When you experience this kind of growth, which is across both the fee-for-service book, the value-based book in existing markets and then also new market entries, we expect we are investing across the spectrum. And then we typically think about this as both as fixed and variable costs. There are certain costs that are variable in nature that would ramp up, mainly pertaining to the new market entries, sales costs, implementation costs as we get more providers in, in those new geographies. But then a lot of the costs are fixed in nature that happen at the upfront as we either enter new geographies or enter into some enhanced capitated arrangements as an example, where we are beefing up some of the capabilities that we have. And you should expect those to scale over time, more G&A in nature, but also some fixed costs in other areas of the company. And then broadly speaking, it is both leadership costs. We're adding a lot of great talent across the organization to support this growth. And then also infrastructure and technology investments.

Yes. The only thing I would add is we report this above the line because it's our -- its ongoing operations. You're going to see us continue to expand and grow the business.

Okay, thanks guys.

Our next question comes from Jailendra Singh with Credit Suisse.

Yes, thank you and good morning everyone. I have a question on your like a long-term outlook. I mean, clearly, 2022 practice collection revenue outlook and EBITDA guidance kind of implies mid-20 to mid-30% growth rate but it does include some puts and takes in terms of new market contract rollouts and investment spending. Just curious with all these puts and takes, I mean, what's your latest thoughts on the long-term revenue and EBITDA growth and margin outlook for the company in like '23 and beyond?

Thanks, Jailendra. Look, when we went public, we had articulated that over a long term, which we define a decade plus, you should expect this business given the substantial TAM that is in front of us, and then also the broad-based platform that we have at Privia, to hopefully deliver 20-plus percent top line growth over that long period of time. And then as the operating leverage kicks in, that would translate into 30-plus percent EBITDA growth. Our hope is we can accelerate that. Obviously, no business grows in that straight-line fashion. You're going to see spikes, and we've experienced that in our recent past as well. So our hope is to keep delivering at a high level, accelerate that as much as possible, make thoughtful investments. The key differentiator for us is we are not sacrificing profitability as we grow. And I think this is a perfect year for '22. As you see, both top line is growing 30%, but EBITDA is also growing 30-plus percent at the midpoint of the guidance. So while we are growing top line at a more accelerated pace than that 20%, we're not really sacrificing EBITDA growth this year, and then we expect to continue that operating leverage in future years.

And just a quick clarification. I mean do those targets include any acceleration in like a shift to full risk capitated arrangements or even your involvement in ACO REACH model if you decided to do so?

Yes. Our view is, it will be across the platform. So whether it's entering new markets, adding providers in existing markets, converting some of the lives we have into capitated arrangements as we did this year, or entering into new value-based program. So again, I think the broad-based drivers are pretty meaningful for us in this platform and allows us to pull many levers, where, as you can see this year, attributed lives and implemented providers are growing double digits -- low double digits. But then that can translate into much more significant practice collections growth given those broad-based drivers.

Okay. And then my follow-up on the comment you guys made earlier about the company's key differentiation being a solid balance sheet and positive cash flow. A couple of questions there. With almost like $300 million in net cash and another strong cash flow you had expected this year. Do you think there are opportunities for you guys to get more aggressive with respect to capital deployment in any way? And second, just a quick number of clarification here. What exactly was $32 million business acquisition you had in the fourth quarter?

Yes, thanks. So I'll take them in line. Number one, just from a capital allocation perspective, look, we think about it in four buckets. First is what we think is a sleep well at night bucket, where in our business as a provider entity that is growing this fast, taking on additional financial risk, we believe we should have significant cushion and have a very conservative balance sheet, low leverage and a solid cash flow profile. That is what helps when the risk presents itself. And our view is not to rely on the capital markets when that happens is that can be very dilutive. Second is, obviously, given the significant TAM that we have, we're looking to continue to invest organically in existing and new markets. The beauty of this business is a lot of that happens on the P&L. And so EBITDA expansion may not happen, but that is part of capital allocation from our perspective. Third is opportunistic M&A. If or when the right opportunity arises. We've not relied on that historically, given how well we've grown organically. And we are fairly disciplined. But whenever that happens, obviously, you want to have some cushion. And then finally, from a completeness perspective, look, if we do have excess cash and the valuation of the business materially differs from what we think is intrinsic value, we can obviously look to return capital in accretive manners to our shareholders. So that's kind of the first part of the question you asked. The second is, the free cash flow generation capability, I think, is truly differentiated. As we articulated, the EBITDA number is fairly straightforward, not too many add-backs. We prefer it that way. It's mainly stock-based comp. And then our business also tends to have this negative working capital or a positive float, which in some periods like in 2021, the phenomena magnifies itself given the timing of cash flows from our payer partners to our medical groups or our risk-bearing entities and then flowing downstream to our physicians. And then obviously, given the minimal CapEx, there's a pretty high EBITDA to free cash flow conversion as far as we're still utilizing our NOLs. The $32 million spend was related to our acquisition of the services platform of BASS MSO in California and the medical group in West Texas.

Got it. Thank you.

Our next question comes from Lisa Gill with JPMorgan.

Thanks very much for taking my question. I hope you can hear me. Just really wanted to follow-up on a couple of things. First off would be the ACO REACH program. I know when we talked in the past about REACH contracting and talking about the expenses being aligned, you also had to say around the governance of your physicians. So, can you give us thoughts around will you participate? And how you're thinking about that program would be my first question. And then my second question would be for David around cash flow. We talked about 90% cash flow conversion. Is that the way we should think about the model going forward when we think about EBITDA conversion?

Hey, Lisa. This is Shawn. We got most of that, I believe. So, I'll take the first part of that. I believe you asked about the ACO REACH program, so I'll talk specifically about that. And with any program, as you know, with us and -- I mean, it's about balancing risk and reward. We thoroughly -- you know, we're going to do the analysis, do it -- we do it internally, as well as sometimes externally, bringing in external consultants to look at those programs. We want to, projecting that risk reward, understanding the different rules, understanding the levers that will make you successful. And as you know, the company has significant experience in MSSP, Medicare Advantage. And the management team goes decades back in government programs. So -- but specific to ACO REACH, there was some incremental improvements in this latest variation, but current -- as it's outlined today, it really doesn't provide the clarity that we would desire for the risk and the additional risk we're assuming. So, our physicians do really, really well in MSSP. You've seen it -- you see it in the results we just published. We're moving some -- additional ACOs, three more into Enhanced, and with two-thirds of our entire book of Medicare -- either Medicare Advantage or MSSP, are in risk programs. So, roughly about -- that books like 245,000 lives. So, I hope that adds -- I hope that's the question you asked on the first part. And the second question was --

Yeah, I'll take the second question. I think it was around EBITDA to free cash flow conversion of 90% and how that moves on forward, if we heard that correctly. So, given we are still running through our NOLs and the stock comp impacts that, I think the cash taxes paid would be a key item on the cash flow statement to look out for. So, the next few years, obviously, the EBITDA to free cash flow conversion would be fairly high around that around the 90-plus percent level. And then once we burn through the NOLs, you'll have to obviously tax affect it. But again, our hope will be they'll be minimal add-backs to get to the adjusted EBITDA number. And then capex would continue to be fairly muted below -- at or below 1 million number.

Great. Thank you very much.

Thank you.

Our next question comes from Jessica Tassan with Piper Sandler.

Hi. Thank you so much for taking the question. Do you guys just mind reminding us what the status or progress is on Privia Care Partners? And what are the expectations for 2022, 2023? Thanks.

Hi, Jess. It's Parth. Thanks for the question. So, as we articulated in our Q3 call, we expected about 30,000 lives in Privia Care Partners. We are running at or ahead of those expectations. Those are included in the guidance we've given today for 2022 and will continue to after that going forward. We're obviously not going to split out the reporting of that number. We don't manage that business separately. It's within all our existing markets. But we are seeing a lot of momentum and are really excited about that product and service offering.

Thanks. And then maybe just as a follow-up, we have some expectations just comparing Privia Care Partners to the full tech stack. Can you maybe help us understand what the financial model is for Privia Care Partners and how it compares on a revenue, care margin, and EBITDA per life base, the full tech stack -- or to the full stack? Thanks.

Yes, sure. So, the margins on the Care Partners book would actually be slightly higher and similar to the margins we have in our value-based book today. We don't break out margins for fee-for-service and value-based, as you know. But generally speaking, the tech stack is a lighter component in the Care Partners model. And the economics are similarly shared. We keep the care management fees, and then the shared savings are split 60/40 between physicians and Privia. So, the economic profile is very similar to the rest of our value-based book. And that's why these lives would be embedded in our ACO attribution that we report going forward.

Got it. Thank you.

Thank you.

Our next question comes from Richard Close with Canaccord Genuity.

Yes, good morning. Thanks for the questions. Can you talk a little bit about the outperformance on practice collections and revenue in the fourth quarter? Was that primarily the new markets that were added? And if you strip that out, what would the growth have been? Parth, you mentioned same-store growth, but maybe you can provide that for us.

Yes. Thanks for the question, Richard. Obviously, the extent of the bid was fairly significant relative to what we guided. And it really was very broad-based. So, there was not one particular element, and there were four key components. So, one was utilization was much, much stronger than what we anticipated, given the omicron variant. Obviously, tough to predict and guide to, but it came in much better than we expected. We also think our practices actually gain market share. So, both utilization being higher. And then on a same-store basis, we added new providers. We saw record-low gross attrition. And on a net basis, we actually grew our same-store, and that contributed pretty significantly. And then the value-based book continued to outperform. We saw some of that outperformance in Q3, but then that continued into Q4. And then finally, both California and West Texas, the new market -- the contribution for the new markets in Q4, it was one quarter, was better than our expectations when we guided back in Q3. So, it was really broad-based, which was great to see, not one particular element that drove that kind of lift.

Okay. And my follow-up question is, you talked a little bit about Surgery Partners and that relationship. And then you also said you're not really looking at additional new markets this year or next year. Is that completely off the table, or how are you thinking about that? Is that just not included in guidance? You also talked about business development being really strong. So, I’m just trying to get a little bit more detail there.

Yes, definitely. So, to be clear, the business development pipeline is really strong. And we are looking to open new markets as soon as we can. Just given the TAM, we are in eight states plus D.C. And so, we are continuing to look actively at opening new markets this year and going forward. What's in our guidance is only the markets we have announced so far, so which is California, Montana, and West Texas, which are the recent new markets alongside our other existing markets. So, much like 2021, where our initial guidance did not include any new markets, we're doing the same in '22. This guidance does not include the impact of any new markets which we may open. The timing on that is uncertain. So as and when we do announce those, we will update our guidance going forward.

In reference to Surgery Partners, I mean, it's -- you think about their business model, running AFCs with physicians, existing and future markets, it lines up with what we do. The site of service, lower cost of care, higher quality. We've been working with Eric's team. Great group, great management team. They just lines up really well with what we do. And, we'll see where the partnership takes us.

Okay. Thank you.

Our last question comes from Ryan Daniels with William Blair.

Hey guys, Nick Spiekhout on for Ryan. Thanks for taking my question. I guess, just a clarification to start. What was the cadence that you said was going to be on that kind of additional 400 providers you expect in 2022?

Hey, Nick. It's Parth. Not sure we fully understand the question. Our guidance at the midpoint is 3,675. And, it'll be spread evenly through the year much similar to the progression you saw in '21. A lot of those providers are sold but not implemented. It takes about six months to implement and get them fully on-ramp. So, you should expect a similar cadence to what we had in 2021 based on that ramp.

Okay. Just in Q4, there was a pretty big jump over Q3. So -- but that was mostly new markets coming online, so it should be pretty kind of evenly spread out throughout the year, is what I'm saying.

That's correct.

Okay, great. Thanks. Appreciate that. And then the next one, I was wondering if you can kind of sort of walk through, at a high level, almost like a waterfall from your 2022 guide versus your expectations from your IPO. So, for example, like how much of the 2022 outperformance from IPO is from 2021 outperformance? How much is from incremental new market entries? And then, how much of that is from moving further kind of down the risk spectrum?

Yes, I appreciate the question. So, look, obviously, we're not going to pinpoint it specifically and break down the practice collections bridge. But generally speaking, again, it was similar to the last question, very, very broad-based. So, what we saw in the existing geographies were three components. One was really good utilization. Second was very strong same-store growth, very low attrition. Thirdly, record new provider adds in existing markets. And all of those were ahead of or better than our expectations. On the value-based book, we performed much better than expectation -- what our initial guidance was in '21 in the existing markets. So, both the MSSP program and other value-based programs during the course of the year. And then, obviously, our initial guidance did not include, in '21, any new markets. So, when we entered California, West Texas, Montana, all of those, obviously, ahead of our expectations from a timing perspective. When that happens, we get this acceleration in top-line growth in the following six to 12 months. So, you're seeing some of that play out in '22. And then, as these providers ramp up, you'll see that come through the course of this year. And then if we add new markets, that would hopefully accelerate it beyond. But we will update that when that happens.

Yes. And that -- the only thing else I'd add, there was the addition of the capitated arrangements slide that we've added. None of those were in our IPO projections.

Okay. Thanks. That's helpful color. Congrats on the quarter, guys.

We have a follow-up question from the line of Richard Close with Canaccord Genuity.

Yes, thanks for squeezing that in. I guess, just a follow-up to Josh's question earlier on with respect in -- with respect to moving the full risk. Do you guys think you need a year or two with Healthfirst and Humana before you feel comfortable moving more lives to pull risks? Or could it be shorter than that?

Yes. Thanks for the question, Richard. Look, our view is we will do enter into these agreements when it makes the most sense, both from a fair perspective on providers and the risk pools we have. So, there's really no cookie-cutter formula, it'll vary by market, and it'll vary based on our ability to manage that pool and make money at the end of the day. And I think that last part really differentiates us. We're not doing it just to get top-line growth and move lives and just recognize that top-line PMPM when you do that based on accounting rules. The key is, can you make money both for the payers? Can we have shared savings? Can we get the patient outcomes? Share that with the payers, share that with our physicians. And we are all in it from a skin-in-the-game perspective. So, I think the answer will just vary. We could have zero additions, or we could double the number of capitated lives. It'll just depends on how we believe the risk pools move and what the best decision might be for the company.

Okay. Thank you.

That concludes today's question-and-answer session. I'd like to turn the call back to Mr. Morris for closing remarks.

Thank you for listening to our call today. Privia Health's proven model supports all providers and all patients across all reimbursement models. Our scalable, capital-efficient, and integrated care delivery model has significant momentum in the physician enablement market. And we look forward to continuing to execute at a high level and delivering accelerated growth in 2022. We appreciate your continued interest in support of our company and look forward to speaking to you soon again. Enjoy the rest of your day, and thank you.

This concludes today’s conference call. Thank you for participating, you may now disconnect.